[{"address1": "1025 Connecticut Avenue NW", "address2": "Suite 1000", "city": "Washington", "state": "DC", "zip": "20036", "country": "United States", "phone": "202-327-5422", "website": "https://www.60degreespharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.", "fullTimeEmployees": 3, "maxAge": 86400, "priceHint": 4, "previousClose": 0.275, "open": 0.268, "dayLow": 0.2672, "dayHigh": 0.282, "regularMarketPreviousClose": 0.275, "regularMarketOpen": 0.268, "regularMarketDayLow": 0.2672, "regularMarketDayHigh": 0.282, "forwardPE": -1.226087, "volume": 193901, "regularMarketVolume": 193901, "averageVolume": 486512, "averageVolume10days": 811800, "averageDailyVolume10Day": 811800, "bid": 0.2709, "ask": 0.2741, "bidSize": 100, "askSize": 100, "marketCap": 3442120, "fiftyTwoWeekLow": 0.201, "fiftyTwoWeekHigh": 8.65, "priceToSalesTrailing12Months": 9.10125, "fiftyDayAverage": 0.26272, "twoHundredDayAverage": 0.53529, "currency": "USD", "enterpriseValue": 10471126, "profitMargins": -1.9438499, "floatShares": 8976545, "sharesOutstanding": 12206100, "sharesShort": 88928, "sharesShortPriorMonth": 130701, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0073, "heldPercentInsiders": 0.23672001, "heldPercentInstitutions": 0.04093, "shortRatio": 0.4, "shortPercentOfFloat": 0.008, "impliedSharesOutstanding": 12206100, "bookValue": -0.226, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -853052, "trailingEps": -0.06, "forwardEps": -0.23, "enterpriseToRevenue": 27.687, "enterpriseToEbitda": -1.907, "52WeekChange": -0.9397436, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SXTP", "underlyingSymbol": "SXTP", "shortName": "60 Degrees Pharmaceuticals, Inc", "longName": "60 Degrees Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1689168600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ad7637e3-b301-3c55-967b-45d771706886", "messageBoardId": "finmb_241910140", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.282, "targetHighPrice": 1.3, "targetLowPrice": 1.3, "targetMeanPrice": 1.3, "targetMedianPrice": 1.3, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 2894700, "totalCashPerShare": 0.238, "ebitda": -5490721, "totalDebt": 158232, "quickRatio": 2.908, "currentRatio": 7.16, "totalRevenue": 378203, "debtToEquity": 2.221, "revenuePerShare": 0.064, "returnOnAssets": -0.43339002, "freeCashflow": -3038976, "operatingCashflow": -5270670, "revenueGrowth": 5.806, "grossMargins": -2.62722, "operatingMargins": -9.11508, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]